Stock Events

Enlivex Therapeutics 

€2.98
2
+€0+0% Wednesday 07:05

Statistics

Day High
2.98
Day Low
2.98
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
71.47M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28FebExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.54
-0.36
-0.18
0
Expected EPS
-0.28
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1BT.F. It's not an investment recommendation.

About

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Show more...
CEO
Mr. Shai Novik M.B.A.
Employees
71
Country
IL
ISIN
IL0011319527
WKN
000A119KH

Listings